Radioactive Drug Research (RDRC)
RADIOACTIVE DRUG RESEARCH COMMITTEE-(RDRC)
LSU Health Shreveport
The purpose of the Radioactive Drug Research Committee (RDRC) is to review the experimental use of radioactive substances in humans. Research projects reviewable by the Committee are designed to obtain basic information regarding metabolism (eg. kinetics, distribution, and localization), human physiology, pathophysiology, or biochemistry of the radiolabeled substance. RDRC review is not applicable to clinical trials which determine therapeutic effectiveness, diagnostic efficacy, or as a clinical tool in research projects for other purposes.
Federal Guidelines stipulate that the RDRC shall be composed of:
1. A person qualified by training & experience to formulate radioactive drugs,
2. A person with special competence in radiation safety & radiation dosimetry, and
3. Physician recognized as specialist in nuclear medicine.
LSUHSC-S Guidelines additionally stipulate that the RDRC shall be composed of:
1. Member of the IRB with knowledge of radioisotopes,
2. Radiation Therapist,
3. Faculty with special knowledge or training in radioisotopes, and
4. Biomedical Research Foundation representative.
FDA recommended that the RDRC be small (5-7 members).
The 2016-2017 RDRC members are from the following departments or outside entities:
- Cardinal Health, Inc
- Radiation Dosimitry
- BRF, PET Operation
- Animal Resources
- Internal Medicine
- Office for Sponsored Programs & Technology Transfer